{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:45Z","timestamp":1787009865616,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"\n Purpose of review<\/jats:title>\n This review discusses the most updated literature of myopathy in scleroderma and other connective tissue diseases.<\/jats:p>\n <\/jats:sec>\n \n Recent findings<\/jats:title>\n In the past year, studies have demonstrated that myopathy in scleroderma is associated with poor outcomes such as disability and mortality. In addition, muscle histopathology in scleroderma continues to reveal that it is a heterogeneous entity, and that necrosis and acute neurogenic atrophy may be a more prevalent histopathologic feature in muscle biopsies than previously reported. In other connective tissue diseases such as SLE, the onset of overlap myositis typically does not occur simultaneously as it does in scleroderma or rheumatoid arthritis.<\/jats:p>\n <\/jats:sec>\n \n Summary<\/jats:title>\n Myopathy in scleroderma is heterogeneous and given that it is associated with poor outcomes, it is imperative that optimal diagnostic strategies and therapies including a classification criterion be developed. In other connective tissue diseases, such as rheumatoid arthritis and systemic lupus erythematosus, myopathy is even more poorly defined and requires more robust studies to clarify both the clinical features and muscle histopathology in this group.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/bor.0000000000000336","type":"journal-article","created":{"date-parts":[[2016,8,20]],"date-time":"2016-08-20T20:37:48Z","timestamp":1471725468000},"page":"631-635","source":"Crossref","is-referenced-by-count":23,"title":["Myopathy in scleroderma and in other connective tissue diseases"],"prefix":"10.1097","volume":"28","author":[{"given":"Julie J.","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/art.1780110405","article-title":"Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)","volume":"11","author":"Medsger","year":"1968","journal-title":"Arthritis Rheum"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/art.1780210111","article-title":"Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations","volume":"21","author":"Clements","year":"1978","journal-title":"Arthritis Rheum"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-004-0975-7","article-title":"Clinical and laboratory features of scleroderma patients developing skeletal myopathy","volume":"24","author":"Mimura","year":"2005","journal-title":"Clin Rheumatol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-4362.1987.tb00580.x","article-title":"Scleroderma-polymyositis overlap syndrome. Clinical and serologic aspects","volume":"26","author":"Mimori","year":"1987","journal-title":"Int J Dermatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2008.095919","article-title":"A descriptive and prognostic study of systemic sclerosis-associated myopathies","volume":"68","author":"Ranque","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0002-8703(93)90075-K","article-title":"Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association","volume":"125","author":"Follansbee","year":"1993","journal-title":"Am Heart J"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ard.28.3.281","article-title":"Skeletal muscle involvement in systemic sclerosis","volume":"28","author":"Thompson","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-014-2730-z","article-title":"Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis","volume":"33","author":"Aguila","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R12-20230829","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22870","article-title":"Severity of muscle weakness independently associates with disability as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) in scleroderma","author":"Paik","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R13-20230829","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J Rheumatol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/ard.2005.050187","article-title":"Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study","volume":"65","author":"Khanna","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3899\/jrheum.090375","article-title":"The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma","volume":"37","author":"Sekhon","year":"2010","journal-title":"J Rheumatol"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2013.868512","article-title":"Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar4562","article-title":"Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology","volume":"16","author":"Bhansing","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord NMD"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/MD.0000000000000523","article-title":"In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome","volume":"94","author":"Meyer","year":"2015","journal-title":"Medicine (Baltimore)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201611000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T02:44:16Z","timestamp":1693277056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201611000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000336","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}